Comparing Lorcaserin Versus Duloxetine for the Treatment of Chemotherapy-Induced Peripheral Neuropathy
A Randomized Phase II Study Comparing Lorcaserin Versus Duloxetine for the Treatment of Chemotherapy-Induced Peripheral Neuropathy Produced by Oxaliplatin
  • Phase

    Phase 2
  • Study Type

  • Status

    Unknown status
  • Study Participants

A Randomized Phase II study Comparing Lorcaserin versus Duloxetine for the Treatment of Chemotherapy-Induced Peripheral Neuropathy Produced by Oxaliplatin
To examine lorcaserin a selective R-HT2c receptor antagonist approved by FDA as weight loss drug- for its ability to improve proprioceptive movements in patients with advanced colorectal cancer who developed neurotoxicity during oxaliplatin-based chemotherapy.
Study Started
Jun 30
Primary Completion
Feb 28
Study Completion
Oct 31
Last Update
Apr 04

Drug Duloxetine 60 mg qd

60 mg tablet Taken by mouth, Once Daily for 180 Days

Drug Lorcaserin

10 mg tablet Taken by mouth Twice Daily for 180 Days

Control Active Comparator

Duloxetine 60 mg qd

Intervention Experimental

Lorcaserin 10 mg bid


Inclusion Criteria:

Subject has a diagnosis of invasive colorectal cancer, locally advanced or advanced, requiring oxaliplatin-based chemotherapy for treatment.
Subject has agreed to receive treatment at Cancer Treatment Centers of America, Southeastern Regional Medical Center.
Subject is Male or Female
Subject is 18 years of age or older.
Subject is a patient who reports neurotoxicity symptom grade 2 or more according CTCAE criteria to his or her medical oncologist following one or more cycles of oxaliplatin-based chemotherapy treatment.
Subject is a patient who is capable and accepting of completing study questionnaires at each data collection point.
Subject has adequate English fluency for completion of data collection. The surveys were designed and validated in English and are not currently available in other languages. Translation of questionnaires into other languages would require reestablishing the reliability and validity of these measures. Therefore, participants must be able to communicate in English to complete the surveys.
Subject must have the ability to understand and the willingness to sign a written informed consent
Subject must be willing to comply with all study procedures and be available for the duration of the study.

Exclusion Criteria:

Subjects who have previously been exposed to neurotoxic agents including pyridoxine (>100 mg/day), colchicine, allopurinol, or phenytoin;
Subjects with pre-existing comorbidities, such as: diabetes, uremia, significant peripheral vascular disease, HIV, or progressive or degenerative neurologic disorders (e.g., multiple sclerosis, B12 deficiency); cardiovascular valve disease, history of cardiovascular event,
Subjects with a history of lumbosacral laminectomy or radiculopathy;
Subjects who have been prescribed and taken gabapentin, pregabalin, or duloxetine currently or within the last 1 months)
Subjects who have established or suspected family history of inherited neuropathy.
Subjects unable to swallow indicated medication
Subjects in general with a medical condition, laboratory finding, or physical exam finding that precludes participation
Subject weight of ≥350 lbs.
Subjects who currently use disallowed concomitant medications
Subjects with any form of cardiac implants
Subjects who report recent febrile illness that precludes or delays participation
Subjects with pregnancy or lactation
Subjects with known allergic reactions to components of the study product(s)
Subjects receiving treatment with another investigational drug or other intervention
Subjects with a history of or current tobacco or illegal substance use
Subjects exhibiting significant psychiatric or cognitive impairment (dementia/delirium, retardation, active psychosis) that in the judgment of the investigators would preclude providing informed consent and study participation.
No Results Posted